Possible takeover28 Mar 2018 13:05
Takeda believes that a potential transaction with Shire presents an opportunity to advance Takeda�s stated Vision 2025, build on its current strong momentum, and create a truly global, value-based Japanese biopharmaceutical leader. In particular, a transaction with Shire would:
� strengthen Takeda�s core therapeutic areas of oncology, GI and neuroscience
� accelerate Takeda�s vision to be a leader in specialized medicines that are transformative to patients through the addition of Shire�s leading global rare disease franchise
� further enhance Takeda�s robust R&D strategy, concentrating on key therapeutic areas
� reinforce a strong and large-molecule focused late-stage pipeline within Takeda�s core therapeutic areas to complement Takeda�s own pipeline and discovery capabilities
� balance Takeda�s geographic focus to align with the market opportunity in the U.S.
� drive financial value from a strong combined financial profile
Clearly defined strategic and financial objectives are core to Takeda�s disciplined approach to acquisitions, including in relation to its dividend policy and credit rating, which are well-established. Any potential offer for Shire, if made, would have to align with this strict investment criteria.